New Study for users of Ocrevus or Kesimpta

[BettysMom]

Participants will be compensated with $$

Dear iConquerMS Member,

We’re reaching out today with an invitation to participate in a new study. This study aims to understand changes in MS symptoms between doses for people with MS who are treated with ocrelizumab (Ocrevus) or ofatumumab (Kesimpta). We’re conducting this study with the pharmaceutical company Novartis and their consultant STATLOG Inc.

Participation involves completing a set of questionnaires at enrollment, and before and after your next two treatment doses. Participants will be compensated $50 for each set of questionnaires that is completed, up to $250 total.

You may be eligible for this study if you:

live in the United States

have been diagnosed with relapsing MS, secondary progressive MS, or clinically isolated syndrome (CIS)

are currently being treated with either Kesimpta or Ocrevus

Kesimpta users: treatment start was at least 6 months ago

Ocrevus users: treatment start was at least 1 year ago, and most recent dose was at least 3 months ago

If you are interested in participating in this study, please email us at [e-mail] and we will send you further information. If you don’t meet the eligibility criteria now but expect to do so in the future, please get in touch to let us know.

Thank you for considering this study, and for being part of the iConquerMS community!

[CatsandCars]

Thank you, that's interesting!

[MountainGrrl]

Just emailed you!